PROCEPT BioRobotics stock: Analysts trim target ahead of Q3 results

Analysts have lowered their price target for PROCEPT BioRobotics ahead of the company's expected third-quarter financial update. Simply Wall St reported the change on October 30, 2026, citing a reduction in the target from USD 62.70 to USD 60.90 despite expectations for healthy quarterly performance.

Target cut keeps earnings in focus

The adjustment reflects a more cautious view of the medical-device company amid broader MedTech market volatility and the possibility of sharp share-price movements around results, according to the analysis. The company is expected to report its third-quarter 2026 figures on November 4, 2026.

For investors, the upcoming report should provide a fresh view of revenue development, operating execution and the path toward profitability. The target reduction does not by itself establish a change in the company's underlying business, and the article does not attribute a specific market move to the revision.

Growth opportunity meets profitability risk

PROCEPT develops robotic systems for urology and generates revenue from its platform and related procedures. Simply Wall St describes annual revenue as forecast to grow, while also identifying the company as currently unprofitable and not expected to become profitable over the next three years.

That combination leaves the investment case dependent on continued adoption, execution and eventual operating leverage. The November results may therefore matter less for a single quarterly figure than for evidence that growth can translate into improving financial performance.

The Simply Wall St analysis frames the target revision against the company's growth expectations and continuing losses.

In the broader US market, investors can follow developments through current S&P 500 market coverage.